← Back to patent-cliff list
布地奈德/昔萘酸沙美特罗
Tier C — Watch / tradeBudesonide/Salmeterol xinafoate
Laboratoires Smb Sa
Originator
2015
First approval
-
Expiry (public)
No sales data
Peak sales
化学药
Type
Targets：ADRB2、GR
Brand：Zephirus、Labazenit
Indications (approved)：哮喘
Regional status
US
-
EU
批准上市
2015-01-01
China
-
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Budesonide/Salmeterol xinafoate?
Approved indications include: 哮喘.
When does the Budesonide/Salmeterol xinafoate patent expire?
No public expiry year is available for Budesonide/Salmeterol xinafoate yet; this page updates once verified.
How do I get a quote for Budesonide/Salmeterol xinafoate intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-24